Company Overview and News

 
KLCI stays above 1,710-level, select blue chips lift

2017-03-06 theedgemarkets
KUALA LUMPUR (March 6): The FBM KLCI remained above the 1,710-point level at mid-morning today, lifted by select blue chips.

 
KLCI dips in line with breather at regional markets

2017-02-24 theedgemarkets
KUALA LUMPUR (Feb 24): The FBM KLCI dipped in early trade this morning in line with the breather at most regional markets.

 
KLCI sees limited gains as sentiment stays nervy

2017-02-06 theedgemarkets
KUALA LUMPUR (Feb 6): The FBM KLCI saw limited gains at the midday break today as sentiment stayed ahead of more corporate earnings announcements to the local bourse this month.

 
KLCI rises 0.37%, stays above 1,660 level

2017-01-06 theedgemarkets
KUALA LUMPUR (Jan 6): The FBM KLCI’s January rally continued today and the FBM KLCI rose 0.37% to stay above the 1,660-point level.

 
KLCI rises 0.48% as finance sector lifts

2017-01-04 theedgemarkets
KUALA LUMPUR (Jan 4): The FBM KLCI rose 0.48% at the midday break today, lifted mainly by gains at stocks in the finance sector.

 
KLCI rises 0.37% as Petronas, banking stocks gain

2017-01-04 theedgemarkets
KUALA LUMPUR (Jan 4): The FBM KLCI rose 0.37% at mid-morning today, lifted by Petronas-related and index-linked banking stocks.

 
KLCI drifts lower, select blue chips weigh

2016-12-30 theedgemarkets
KUALA LUMPUR (Dec 30): The FBM KLCI drifted lower at the midday break today, weighed by select blue chips.

 
KLCI reverses losses, rises on window dressing activities

2016-12-30 theedgemarkets
KUALA LUMPUR (Dec 30): The FBM KLCI reversed its earlier losses and edged up at mid-morning today, lifted by select blue chips on some mild year-end window dressing.

 
KLCI to trend higher on final trading day of 2016, eye 1,640 level

2016-12-29 theedgemarkets
KUALA LUMPUR (Dec 30): The FBM KLCI is expected to trend higher on the final trading day of 2016 and inch toward the 1,640-point level.

 
BCorp, Crescendo, Apollo Food, Quality Concrete, SMTrack and FoundPac

2016-12-29 theedgemarkets
KUALA LUMPUR (Dec 29): Based on corporate announcements and news flow today, stocks that will be in focus on Friday (Dec 30) may include: BCorp, Crescendo, Apollo, Quality Concrete, SMTrack and FoundPac.

 
Bursa Malaysia ends morning session lower

2016-12-22 themalaymailonline
KUALA LUMPUR, Dec 22 ― The benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) ended the morning session today on a negative note, due to the lack of buying activities in heavyweights, as well as small caps and lower liners.

 
KLCI remains in negative zone in tandem with region

2016-12-22 theedgemarkets
KUALA LUMPUR (Dec 22): The FBM KLCI remained in the negative zone at the midday break in tandem with struggling regional markets.

 
KLCI dips 0.21% on tepid sentiment

2016-12-16 theedgemarkets
KUALA LUMPUR (Dec 16): The FBM KLCI remained in negative territory at the midday break today, in tandem with the weaker regional markets.

 
KLCI struggles in line with region but pares loss

2016-12-16 theedgemarkets
KUALA LUMPUR (Dec 16): The FBM KLCI struggled in line with regional markets but pared some of its loss at mid-morning today.

 
KLCI pares gains on market close as ringgit weakens

2016-12-13 theedgemarkets
KUALA LUMPUR (Dec 13): The FBM KLCI pared gains it made earlier in the day — supported by oil producing countries’ decision to reduce crude oil output — to close 3.86 points or 0.24% higher at 1,645.28 points.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

23h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...